METHODE POUR PURIFIER UNE SUSPENSION DE LIPOSOMES

METHOD FOR PURIFYING A LIPOSOMIC SUSPENSION

Abrégé anglais

ABSTRACT OF THE DISCLOSURE
A method is disclosed for purifying a liposomic suspen-
sion from a non-entrapped free drug by contacting same with an
ion exchange resin either in the activated or the non-activated
form. The resin may be of the anioinic type or the cationic type,
and either strong or weak. The liposomic suspension, thus purified,
may thereafter be lyophilized for the purpose of stabilizing same.
The purified liposomic suspension and the stabilized purified
liposomic suspension are also part of the invention. An adsorbent
resin may also be used.

Revendications

The embodiments of the invention in which an exclusive
property or privilege is claimed are defined as follows:
1. A method for purifying a liposomic suspension which
consists of a drug contained in corpuscles or globules consisting
of aqueous and lipidic concentric layers, said method comprising
contacting said suspension with a compound selected from the
group consisting of an activated ion exchange resin, a non
activated ion exchange resin and an adsorbent polymeric substance.
2. A method as claimed in claim 1 wherein said resin is
a strong anionic resin.
3. A method as claimed in claim 1 wherein said resin is
a weak anionic resin.
4. A method as claimed in claim 1 wherein said resin is a
strong cationic resin.
5. A method as claimed in claim 1 wherein said resin is
a weak cationic resin.
6. A method as claimed in claim 1 further including the
step of lyophilizing said purified suspension.
7. A method as claimed in claim 1 wherein said lipidic
layer consists of a phospholipid, a steroid and an ionic tensio-
active or surface active substance.
8. A method as claimed in claim 7 wherein said phosphol-
ipid is lecithin or sphyngomyelin.
9. A method as claimed in claim 7 wherein said steroid
is cholesterol.

10. A method as claimed in claim 7 wherein said ionic
tensioactive or surface active substance is selected from the
group consisting of dicetylphosphate, stearylaminee and
phosphatidic acid.
11. A method as claimed in claim 1 wherein said drug is
contained in globules of aqueous and lipidic concentric layers.
12. A method as claimed in claim 1 wherein said compound
is added to said suspension, shaken and then filtered.
13. A method as claimed in claim 12 wherein said filtration
is carried out through a porous sheet which retains said compound
on which the free drug has been adsorbed.
14. A method as claimed in claim 13 wherein said porous
sheet is made of sintered glass filter material.
15. A method as claimed in claim 11 wherein the diameter of
said globules is from about 0.01/µ to about 5/µ.
16. A purified liposomic suspension which consists of layers
of aqueous and lipidic concentric layers whenever prepared by the
process as claimed in claim 1.
17. A stabilized and purified liposomic suspension which
consists of layers of aqueous and lipidic concentric layers
whenever prepared by the process as claimed in claim 6.
18. A purified liposomic suspension as claimed in claim 16
wherein said lipidic layer consists of a phospholipid, a steroid
and an ionic tensioactive or surface active substance.
19. A stabilized and purified liposomic suspension as
claimed in claim 17 wherein said lipid layer consist of a
phospholip, a steroid and an ionic tensioactive or surface active
substance.

Description

i5~F~
1 This invention relates to a new method ~or preparing
injectable liposomes.
Liposomes are a pharmaceu-tical composition in which the
drug is contained in corpuscles or globules consisting of aqueous
and lipidic concentric layers. The drug may be present in either
or both of the aqueous and/or lipidic layers. The lipidic layer
comprises or consists generally of a phospholipid, such as
lecithin and sphyngomyelin; a steroid, for example cholesterol;
and an ionic tensioactive or surface active substance, such as
dicetylphosphate, stearylamine and phosphatidic acid. The dia-
meter ofliposomes ranges from 0.01 to 5 ~. The procedure usually
employed for preparing liposomes comprises two main stepso
1. Preparation of liposomes. The lipidic components are
dissolved in chloroform, which is then evaporated under vacuum.
In the flask containing the residue as a thin layer, the drug
solution is added and the whole is subjected to ultrasonic shaking
for a time ranging from 30 seconds to 12 hours. The liposomic
suspension so obtained contains an important fraction of non-
entrapped drug which must be separated ~rom the liposomes.
2. Separation of the liposomec, from the non-entrapped
drug. This procedure is carried out by column chromatograph~ with `
e.g. Sepharose 6B as a molecular sieve material. Sepharose is a
registered trademark for spherical agarose gel beads manufactured
by Pharmacia Fine Chemicals AB. The "6B" refexs to an agarose
concentration of about 6% and a particle size in the wet state of
about 40 to 210,u. The liposomes eluate first, whereas the free
drug is retained by the Sepharose.
Another suitable procedure is ultracentrifuga-tion at
lOO,OOOg and subsequent washing, always by unltracentrifugation,
with buffered solution.
--1--

~lfiS~
1 The liposomes have demons-trated, in the animal, an abil-
ity to direct antitumoral drugs selectively toward neoplastic
cells.
The presen-t invention relates to a new procedure for
separatiny liposomes from non-entrapped drug. It utilizes ion-
exchange and adsorbent resins without the necessity of employing
chromatography. The ion-exchange resin is added to the liposomic
suspension of the drug which is to be purified, and the whole
shaken for 1-120 minutes.
The free liposomic suspension is ob-tained after filtra-
tion through porous sheet that retains the resin on which the free
drug has been adsorbed. A suitable porous sheet is one made e.g.
of a sin-tered glass filter material, such as manufactured by the
German firm Jena er Glaswerk Schott 8 Gen. Mainz that produces a
wide range o~ suitable glasses. These glasses are named with
different alphabetical letters and numbers (e.g. Gl : in this case
number 1 reEers to the broader pores generally used in filtration).
The pore size abviously changes. The alphabetical letter refers
to the kind of sintered glass that also changes depending on the
eventual desired transfer o~ residue due to filtration.
This new purification procedure, utilizing ion-exchange
resins, shows the great advantage of giving very concentrated
liposomic suspensions (up to 4 mg/ml of Adriamycin hydrochloride)
which cannot be achieved by chromatography with molecular sieves
~max 200 r/ml). The liposomic suspension so obtained is very
stable and is not inclined to sedimentation in contrast to the
suspensions obtained by ultracentrifugation at high r.p.m.'s.
The desired chemical stabilization is achieved by
lyophilization of the liposomic suspension.
The following examples are provided to still further
illustrate the invention but without limiting it:
--2--

L6~
1 FXAM E 1
In a saponiEication flask, l.5 y of egg lecithin, 0.4 g
of cholesterol, and 0.2 g of dicetylphosphate were dissolved in
chloroform and the solvent evaporated to dryness. An adriamycin
hydrochloride solution (concentration 20 mg/ml) in 0.007 N buffer
phosphate was then added and the resulting solution was subjected
to ultrasonic shaking for one minute.
The suspension was then allowed to stand at room temper-
ature under a nitrogen atmosphere for 30 minutes, then 2 g of
BDH IR-50 resin (a granular-polymeric resin manufactured by R~hm
Haas), previously activated in the sodium form, were added
(weight refers to dry weight and is equivalent to 5 ml of inflated
resin. By "inflated resin" is meant that the resin has been
activated by two successive treatments, first in a 4% HCl solution
and then in a 4~ NaOH solution).
The flask was subjected for 30 minutes to shaking; the
suspension was then filtered over a porous sintered glass sheet
Gl.
Liposomes of size varying from 0.5 to 2~1 and containing
~O 20% of the starting amount of adriamycin have been obtained. They
were made stable by lyophilization.
EXAMPLE 2
Operating as described in Example l, and employing the
same amounts of adriamycin and lipids, the ultrasonic shaking time
was extended to lQ minutes in order to obtain liposomes of size
less than l,u. A non-granular resin, having also the function of
a sieve, was selected in view of the fact that the whole body of
the liposomes is not perfectly homogeneous in size.
Accordingly, l0 ml of DOWEX 50W-X 4 100-200 mesh resin
(a macroreticular resin available from Dow), and previously
Trade Marks -3-
,,~ j

~L65~
1 a~tivated in sodium form, were introduced into the flask. After
filtration, a suspension was ob-tained containing liposomes ranging
from 0.2 and ~.8~ in size and containing 12% of the starting
adriamycin. The liposomes were then made sta~le by lyophilization.
EXAMPLE 3
A solution of 5-fluorouracil at a concentration of
10 mg/ml in 0.007N buffer phosphate and pH 8, was poured into the
saponification flask containing the lipidic phase prepared as
previously described. The suspension was treated as in Example 1,
using as filtering resin 10 ml of Amberlite IRA-400 (Cl), a
granular polymeric resin produced by Rohm & Haas, previously
activated as the hydrochloride. The liposomes so obtained were
made sta~le by lyophilization.
EXAMPLE 4
Liposomes of 5-fluorouracil were prepared as prevlously
described utilizing 1.5 g of egg lecithin, 0.4 g of cholesterol,
and 0.2 g of stearylamine. As the purification agent 10 ml of a
previously activated DOWEX 1 resin (50-100 mesh), a granular poly-
meric resin available from Dow, were used. The liposomes so ob-
tained were stabilized by lyophilization.
EXAMPLE 5
Operating under the same conditions and with the same
amounts as in Example 2, an adriamycin liposomic suspension was
prepared, purified by usiny 15 g of adsorbing Rohm h Haas XAD 7
resin (a granular polymeric resin), directly placed into the pre-
paration flask.
A~ter shaking for 40 minutes and filtration through
sintered filter glass Gl, a suspension of liposomes containing
about 50% of the startiny quanti-ty of adriamycin was obtained,
which was then stabilized as before by lyophilization.
Trade Marks -4-
~ 1